Literature DB >> 18221607

Coagulopathy in liver disease.

Wojciech Blonski1, Timothy Siropaides, K Rajender Reddy.   

Abstract

The liver plays a central role in hemostasis, as it is the site of synthesis of clotting factors, coagulation inhibitors, and fibrinolytic proteins. The most common coagulation disturbances occurring in liver disease include thrombocytopenia and impaired humoral coagulation. Therapy's overall goal is not to achieve complete correction of laboratory value abnormalities but to gain hemostasis. Therapy with vitamin K may be a useful option in patients with increased prothrombin time due to vitamin K deficiency; in patients with malnutrition; in patients using antibiotics; and in patients with cholestatic liver disease, particularly prior to invasive procedures. Infusion of fresh frozen plasma is more often effective and is recommended in patients with liver disease before invasive procedures or surgery, as such patients require transient correction in their prothrombin time. Therapy with plasma exchange may be considered in patients who cannot be treated with fresh frozen plasma due to volume overload risk. In patients with severe coagulopathy and hypofibrinogenemia, cryoprecipitate therapy is ideal. Therapy with prothrombin-complex concentrate is seldom pursued in patients with liver disease due to high risk of thrombotic complications. Transfusions of platelets are appropriate for patients with thrombocytopenia (< 50,000/mm(3)) associated with active bleeding or before invasive procedures in which a short-term platelet count increase is noted. Trial with desmopressin may be considered before invasive procedures in patients with liver disease and with refractory and prolonged bleeding time. Recombinant activated factor VIIa administration is suggested for patients with significantly prolonged prothrombin time and contraindications to fresh frozen plasma therapy; however, this is expensive. Thrombopoietin and interleukin-11 are currently investigational for patients with thrombocytopenia of chronic liver disease. Liver transplantation completely restores impaired coagulation abnormalities and is the ultimate intervention that corrects coagulopathy of advanced liver disease and liver failure.

Entities:  

Year:  2007        PMID: 18221607     DOI: 10.1007/s11938-007-0046-7

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  39 in total

1.  Burden of liver disease in the United States: summary of a workshop.

Authors:  W Ray Kim; Robert S Brown; Norah A Terrault; Hashem El-Serag
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

2.  Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy.

Authors:  Andrew Y C Wong; Michael G Irwin; Theresa W C Hui; Serena K Y Fung; S T Fan; Edmond S K Ma
Journal:  Can J Anaesth       Date:  2003-01       Impact factor: 5.063

Review 3.  Haemostatic abnormalities in patients with liver disease.

Authors:  Ton Lisman; Frank W G Leebeek; Philip G de Groot
Journal:  J Hepatol       Date:  2002-08       Impact factor: 25.083

4.  Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study.

Authors:  H G Hendriks; K Meijer; J T de Wolf; I J Klompmaker; R J Porte; P J de Kam; A J Hagenaars; T Melsen; M J Slooff; J van der Meer
Journal:  Transplantation       Date:  2001-02-15       Impact factor: 4.939

5.  Role of plasmapheresis in the management of acute hepatic failure in children.

Authors:  A L Singer; K M Olthoff; H Kim; E Rand; G Zamir; A Shaked
Journal:  Ann Surg       Date:  2001-09       Impact factor: 12.969

6.  Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial.

Authors:  Jaime Bosch; Dominique Thabut; Flemming Bendtsen; Gennaro D'Amico; Agustín Albillos; Juan González Abraldes; Soeren Fabricius; Elisabeth Erhardtsen; Roberto de Franchis
Journal:  Gastroenterology       Date:  2004-10       Impact factor: 22.682

7.  Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant.

Authors:  D F O'Shaughnessy; C Atterbury; P Bolton Maggs; M Murphy; D Thomas; S Yates; L M Williamson
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

8.  Recombinant factor VIIa improves coagulopathy caused by liver failure.

Authors:  Jeffrey B Brown; Karan M Emerick; Deborah L Brown; Peter F Whitington; Estella M Alonso
Journal:  J Pediatr Gastroenterol Nutr       Date:  2003-09       Impact factor: 2.839

9.  Appraisal of concomitant splenectomy in liver resection for hepatocellular carcinoma in cirrhotic patients with hypersplenic thrombocytopenia.

Authors:  Cheng-Chung Wu; Shao-Bin Cheng; Wai-Meng Ho; Jung-Ta Chen; Dah-Cherng Yeh; Tse-Jia Liu; Fang-Ku P'eng
Journal:  Surgery       Date:  2004-09       Impact factor: 3.982

10.  Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model.

Authors:  Raúl Tonda; Ana María Galán; Marcos Pino; Isabel Cirera; Jaume Bosch; María Rosa Hernández; Antonio Ordinas; Ginés Escolar
Journal:  J Hepatol       Date:  2003-12       Impact factor: 25.083

View more
  5 in total

Review 1.  [Coagulation management in patients with liver disease].

Authors:  A Bienholz; A Canbay; F H Saner
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-05-05       Impact factor: 0.840

2.  Paraneoplastic bleeding disorder due to isolated hypofibrinogenemia: a case report.

Authors:  Z Cvetkovic; B Cvetkovic; D Cvetkovic; V Libek; G Perunicic-Pekovic
Journal:  Hippokratia       Date:  2009-01       Impact factor: 0.471

Review 3.  Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.

Authors:  Shannon W Finks; Toby C Trujillo; Paul P Dobesh
Journal:  Ann Pharmacother       Date:  2016-02-25       Impact factor: 3.154

4.  In Vivo and In Vitro Evaluation of Pharmacological Potentials of Secondary Bioactive Metabolites of Dalbergia candenatensis Leaves.

Authors:  Md Anisuzzman; Md Mahedi Hasan; Amit Kumar Acharzo; Asish Kumar Das; Sinthia Rahman
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-26       Impact factor: 2.629

Review 5.  Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study.

Authors:  A A Hanke; C Joch; K Görlinger
Journal:  Br J Anaesth       Date:  2013-01-18       Impact factor: 9.166

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.